Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 10Brain Neoplasms 3Urogenital Diseases 2Neoplasms 2Recurrence 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Glioblastoma 1Disease 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × fluciclovine F-18 × Clear all
NCT03081884 2021-01-25

EDRN-FACBC

Emory University

Phase 2 Completed
61 enrolled 6 charts
Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT02830880 2020-01-07

FACBC Prostate Therapy Response

Emory University

Phase 2 Completed
7 enrolled 10 charts
Genitourinary

Urogenital Diseases, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡